{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:39:23Z","timestamp":1791506363520,"version":"4.3.4"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Understanding the precise mechanism of vaccine-induced protection and the immune correlates of protection against coronavirus disease 2019 (COVID-19) is crucially important for developing next-generation vaccines that confer durable and protective immunity against COVID-19. Similar factors are also important for other infectious diseases. Here, I briefly summarize the mechanism of action of the currently used COVID-19 mRNA vaccines from the viewpoint of the function of the lymphatic system.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1041025","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T07:27:04Z","timestamp":1666250824000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["The lymphatic system and COVID-19 vaccines"],"prefix":"10.3389","volume":"13","author":[{"given":"Masayuki","family":"Miyasaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review","volume":"344","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B3","unstructured":""},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732690","article-title":"Angiotensin-converting enzyme 2 (ACE2) in the pathogenesis of ARDS in COVID-19","volume":"12","author":"Kuba","year":"2021","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMra2206573","article-title":"Covid-19 vaccines \u2014 immunity, variants, boosters","volume":"387","author":"Barouch","year":"2022","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"387","author":"Polack","year":"2020","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: Principles, delivery and clinical translation","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discovery"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.add2897","article-title":"Cell iimmunity to COVID-19 vaccines","author":"Wherry","year":"2022","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020147","article-title":"SARS-CoV-2 mRNA vaccines: Immunological mechanism and beyond","volume":"9","author":"Bettini","year":"2021","journal-title":"Vaccines"},{"key":"B15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-med-042420-112725","article-title":"mRNA vaccines in the COVID-19 pandemic and beyond","author":"Hogan","year":"2022","journal-title":"Ann Rev Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.20965\/jdr.2022.p0007","article-title":"Effectiveness of and immune responses to SARS-CoV-2 mRNA vaccines and their mechanisms","volume":"17","author":"Gohda","year":"2022","journal-title":"J Disast Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2204336119","article-title":"The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2","volume":"119","author":"Townsend","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05716.x","article-title":"Mechanisms of chylomicron uptake into lacteals","author":"Dixon","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114325","article-title":"In vivo fate and intracellular trafficking of vaccine delivery systems","volume":"186","author":"Lee","year":"2022","journal-title":"Adv Drug Delivery Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal2094","article-title":"Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake","volume":"9","author":"Liang","year":"2017","journal-title":"Sci Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient targeting and activation of antigen-presenting cells In vitro and In vivo after modified mRNA vaccine administration in rhesus macaques","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-019-0378-3","article-title":"Visualization of early events in mRNA vaccine delivery in non-human primates via PET\u2013CT and near-infrared imaging","author":"Lindsay","year":"2019","journal-title":"Nat BioMed Engin"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05314-2","article-title":"Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA covid-19 vaccine: Incidence assessed by [18F]FDG PET-CT and relevance to study interpretation","author":"Cohen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220543","article-title":"US Evaluation of axillary lymphadenopathy following COVID-19 vaccination: A prospective longitudinal study","volume":"305","author":"Ha","year":"2022","journal-title":"Radiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080848","article-title":"Antigen presentation of mRNA-based and virus-vectored SARS-CoV-2 vaccines","author":"Rijkers","year":"2021","journal-title":"Vaccines"},{"key":"B29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41541-021-00369-6","article-title":"Distinguishing features of current COVID-19 caccines: Knowns and unknowns of antigen presentation and modes of action","author":"Heinz","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/vaccines9010061","article-title":"Immune responses induced by mRNA vaccination in mice, monkeys and humans","author":"Cagigi","year":"2021","journal-title":"Vaccines"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.161.11.5943","article-title":"Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions","volume":"161","author":"Behrens","year":"1998","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10060866","article-title":"What should we do after the COVID-19 vaccination? vaccine-associated diseases and precautionary measures against adverse reactions","author":"Awaya","year":"2022","journal-title":"Vaccines"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1038\/s41467-022-31485-z","article-title":"Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents","author":"Rosa Duque","year":"2022","journal-title":"Nat Comm"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-Specific humoral and cellular immunity in COVID-19 convalescent individuals","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.1038\/s41467-020-19943-y","article-title":"Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19","volume":"11","author":"Li","year":"2020","journal-title":"Nat Comm"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00025-2","article-title":"Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: A longitudinal study","author":"Chia","year":"2021","journal-title":"Lancet Microbe"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxab008","article-title":"COVID-19 and immunity: Quo vadis","author":"Miyasaka","year":"2021","journal-title":"Int Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1038\/s41467-022-32573-w","article-title":"Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort","author":"Menges","year":"2022","journal-title":"Nat Comm"},{"key":"B39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2021.12.026","article-title":"SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans","author":"Mudd","year":"2022","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg5021","article-title":"Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients","volume":"6","author":"Notarbartolo","year":"2021","journal-title":"Sci Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.05.010","article-title":"Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease","author":"Bergamaschi","year":"2021","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory b cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13263","article-title":"Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover","volume":"31","author":"Soresina","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04778-y","article-title":"Increased memory b cell potency and breadth after a SARS-CoV-2 mRNA boost","author":"Muecksch","year":"2022","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2206576","article-title":"Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5","author":"Hachmann","year":"2022","journal-title":"Pro Nat Acad Sci USA"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.405","article-title":"Antibody-dependent enhancement of viral infection: Molecular mechanisms and In vivo implications","author":"Takada","year":"2003","journal-title":"Rev Med Biol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1016\/j.cell.2021.05.032","article-title":"An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33611\/trs.2021-021","article-title":"Infectivity-enhancing antibodies against SARS-CoV-2","author":"Liu","year":"2022","journal-title":"Translat Regul Sci"},{"key":"B55","doi-asserted-by":"publisher","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Region Health Europe"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.812729","article-title":"Cellular responses to membrane and nucleocapsid viral proteins are also boosted after SARS-CoV-2 spike mRNA vaccination in individuals with either past infection or cross-reactivity","author":"Vallejo","year":"2021","journal-title":"Front Microbiol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination","author":"Tang","year":"2022","journal-title":"Sci Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1041025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T01:55:02Z","timestamp":1678326902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1041025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2022.1041025"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1041025","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"article-number":"1041025"}}